

**A high-throughput amplicon screen for somatic *UBA1* variants in Cytopenic and Giant Cell
Arteritis cohorts**

Supplementary Tables

Supplementary Table 1 – Summary of cytopenia cohort

Supplementary Table 2 – Summary of GCA cohort

Supplementary Table 3 – Primers used for amplicon sequencing

Supplementary Methods

UBA1 exon 3 pooled amplicon sequencing

Supplementary Table 1 - Summary of cytopenia cohort

Age (n=1055)

Mean 68.0
Median 72
Range 18-94

Gender

Males 595
Females 459

Whole Cohort (n=1055)

	wbc	rbc	hb	hct	mcv	plt	lymph %	mixed %	neutr %
Mean	5.53	4.35	113.63	33.64	91.02	148.43	28.86	13.84	58.08
Median	4.8	3.69	113	33	90.2	115.5	26.1	12.4	60.7
Range	0.9-21.4	1.52-141	33.9-174	16.9-97.7	59.8-182	0-764	1-78.3	1.1-51.2	12.5-95.5
Missing data	473	473	473	473	473	471	473	473	473

wbc, white blood count; rbc, red blood count; hb, haemoglobin; hct, ; mcv, ; plt, platelets; lymph%, percentage lymphoid, mixed %, ; neutr %, percentage of neutrophils

Supplementary Table 2 - Summary of GCA cohort

Age (n=361 with available data)

Median	71
IQR	10

Gender (n=361 with available data)

Males	612
Females	0

Blood Biochemistry (at presentation)

	n =	Median	IQR
ESR (mm/hr)	361	61	56
CRP (mg/L)	361	63	89
Platelets (x10 ⁹ /L)	361	334	167
Missing Data	251		

Reported phenotypes associated with GCA

	yes	no	unknown
Neoplasia	33	338	241
PMR symptoms	181	376	55
Ischemic complications	30	313	269

Supplementary Table 3 – Primers used for amplicon sequencing

Primer Name	Sequence 5'-3' (sequencing adapter – index – <i>UBA1</i> primer)
UBA1-i7_A-F	ACACTCTTTCCCTACACGACGCTCTTCCGATCT-GTGAATAT-TGTCTGTCTATCCATGCTCCAC
UBA1-i7_B-F	ACACTCTTTCCCTACACGACGCTCTTCCGATCT-ACAGGCGC-TGTCTGTCTATCCATGCTCCAC
UBA1-i7_C-F	ACACTCTTTCCCTACACGACGCTCTTCCGATCT-CATAGAGT-TGTCTGTCTATCCATGCTCCAC
UBA1-i7_D-F	ACACTCTTTCCCTACACGACGCTCTTCCGATCT-TGCGAGAC-TGTCTGTCTATCCATGCTCCAC
UBA1-i7_E-F	ACACTCTTTCCCTACACGACGCTCTTCCGATCT-TCTCTACT-TGTCTGTCTATCCATGCTCCAC
UBA1-i7_F-F	ACACTCTTTCCCTACACGACGCTCTTCCGATCT-CTCTCGTC-TGTCTGTCTATCCATGCTCCAC
UBA1-i7_G-F	ACACTCTTTCCCTACACGACGCTCTTCCGATCT-CCAAGTCT-TGTCTGTCTATCCATGCTCCAC
UBA1-i7_H-F	ACACTCTTTCCCTACACGACGCTCTTCCGATCT-TTGGACTC-TGTCTGTCTATCCATGCTCCAC
UBA1-i5_1-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-CTAGCGCT-CCACCCAACCTTATCCTCTC
UBA1-i5_2-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-TCGATATC-CCACCCAACCTTATCCTCTC
UBA1-i5_3-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-CGTCTGCG-CCACCCAACCTTATCCTCTC
UBA1-i5_4-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-TACTCATA-CCACCCAACCTTATCCTCTC
UBA1-i5_5-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-CGCTATGT-CCACCCAACCTTATCCTCTC
UBA1-i5_6-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-TATCGCAC-CCACCCAACCTTATCCTCTC
UBA1-i5_7-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-TCTGTTGG-CCACCCAACCTTATCCTCTC
UBA1-i5_8-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-CTCACCAA-CCACCCAACCTTATCCTCTC
UBA1-i5_9-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-CCGCGGTT-CCACCCAACCTTATCCTCTC
UBA1-i5_10-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-TTATAACC-CCACCCAACCTTATCCTCTC
UBA1-i5_11-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-CAAGCTAG-CCACCCAACCTTATCCTCTC
UBA1-i5_12-R	GACTGGAGTTCAGACGTGTGCTCTTCCGATCT-TGGATCGA-CCACCCAACCTTATCCTCTC
UBA1-3F	TGTCTGTCTATCCATGCTCCAC
UBA1-3R	CCACCCAACCTTATCCTCTC

Supplementary Methods

UBA1 exon 3 pooled amplicon sequencing

Primers containing a *UBA1* priming sequence, unique 8bp index and partial Illumina sequencing adapters (Supplementary Table 3) were manufactured by Integrated DNA Technologies (Leuven, Belgium). Unique combinations of 8 forward and 12 reverse primers were pooled in a 96 well plate to allow demultiplexing of sequenced data. 50-100ng of genomic DNA was amplified in 96 well plates using High-Fidelity Phusion 2x Mastermix (Thermo Fisher Scientific) and 5uM of each primer pair. Following amplification, 2ul of each PCR product was pooled and an AMPure bead (Beckman Coulter, High Wycombe, UK) clean-up performed using a 1:1 volume ratio of AMPure beads:DNA. 25ul of each pool at a concentration of 20ng/ul was sequenced using a 250bp paired-end read protocol on an Illumina MiSeq (Genewiz, Boston, USA).